Blutungskomplikationen unter oraler Antikoagulation

Claudia Stöllberger; Peter Pommer; Birke Schneider

doi:10.1055/s-0041-100151

DMW – Klinischer Fortschritt, Inhaltsverzeichnis

Dtsch Med Wochenschr 2015; 140(03): 213
DOI: 10.1055/s-0041-100151

Fachwissen

Leserbrief

Blutungskomplikationen unter oraler Antikoagulation

Bleeding complications under oral anticoagulation

Autor*innen

Claudia Stöllberger

¹2. Medizinische Abteilung mit Kardiologie und internistischer Intensivmedizin, Krankenanstalt Rudolfstiftung, Wien
Peter Pommer

²Gesundheitszentrum Oberammergau, Oberammergau
Birke Schneider

³Medizinische Klinik II, Kardiologie und Angiologie, Sana Kliniken Lübeck

Abstract

Volltext

Referenzen

Literaturverzeichnis
1 Beyer-Westendorf J. Blutungskomplikationen unter oraler Antikogulation. Dtsch Med Wochenschr 2014; 139: 2491-2493
2 Beyer-Westendorf J, Förster K, Pannach S et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962
3 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151
4 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011 365: 981-992
5 Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953
6 Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-334
7 Le Heuzey JY, Ammentorp B, Darius H et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833-841
8 Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 12.12.2012; 12 MR000033
9 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891
10 Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-328
11 Rosenman MB, Simon TA, Teal E et al. Perceived or actual barriers to warfarin use in atrial fibrillation based on electronic medical records. Am J Ther 2012; 19: 330-337
12 Ruff CT, Giugliano RP, Braunwald E et al. New oral anticoagulants in patients with atrial fibrillation – Authors’reply. Lancet 2014; 384: 25-26
13 Zimetbaum PJ, Thosani A, Yu H et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?. Am J Med 2010; 123: 446-453